Bexar County, TX's Series 2013 Combination Tax And Revenue Certificates Of Obligation Rated 'AA+' Jan 13

  • ID: 2384361
  • January 2013
  • Standard & Poors
1 of 3

DALLAS (Standard & Poor's) Jan. 24, 2013--Standard & Poor's Ratings Services assigned its 'AA+' rating to Bexar County, Texas' series 2013 combination tax and revenue certificates of obligation. At the same time, Standard & Poor's affirmed its 'AA+' long-term rating and underlying rating (SPUR) on the county's general obligation debt outstanding. The outlook is stable. "The ratings reflect our view of the county's diverse and expanding economy, very diverse property tax base, and very strong levels of reserves," said Standard & Poor's credit analyst Lauren Spalten. County officials will use certificate proceeds primarily to fund capital improvement projects related to U.S. Highway 281 and Loop 1604 transportation. RELATED CRITERIA AND RESEARCH USPF Criteria: GO Debt, Oct. 12, 2006...

Companies mentioned in this report are:
- Bexar Cnty

Action: Affirmed
Action: New Rating
Action: Outlook: Stable

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Bexar Cnty

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.